Program
Adjuvant
Also written as “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, “Matrix-M2 Adjuvant (25μg)” and “Matrix-M2 Adjuvant (50μg)”.
Its studies are mostly in Influenza, Human · Herpes Simplex · Herpes Zoster · Malaria · Respiratory Syncytial Virus Infections, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Genocea Biosciences | 30 open or running | phase 2since Apr 11, 2014 | Nov 19, 2013 | none ahead |
| BioTech Tools | 20 open or running | phase 2since Dec 7, 2011 | Apr 20, 2010 | none ahead |
| Novavax | 20 open or running | phase 1since May 2, 2012 | May 2, 2012 | none ahead |
| colby-pharmaceutical-company | 10 open or running | phase 1since Apr 15, 2008 | Apr 15, 2008 | none ahead |
| Guangzhou Patronus Biotech | 11 open or running | phase 1since May 28, 2024 | May 28, 2024 | none ahead |
| Immune Targeting Systems | 10 open or running | phase 1since Oct 3, 2012 | Oct 3, 2012 | none ahead |
| MAXVAX Biotechnology Limited Liability | 10 open or running | phase 1since Nov 16, 2022 | Nov 16, 2022 | none ahead |
| Medigen Vaccine Biologics | 10 open or running | phase 2since Apr 27, 2015 | Apr 27, 2015 | none ahead |
| Sanofi | 10 open or running | phase 1since Jun 25, 2020 | Jun 25, 2020 | none ahead |
| Serum Institute of India Pvt. | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Nov 2027phase 2 · NCT07147400 |
| Yikang Biotech (Suzhou) | 11 open or running | phase 1since Sep 1, 2026 | Sep 1, 2026 | Jan 22, 2027phase 1 · NCT07807449 |
Also a collaborator on its studies: yantai-patronus-biotech-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 15, 2008First study: phase 1 study in Influenza, HumanNew to colby-pharmaceutical-companycolby-pharmaceutical-company · NCT00662272 · 128 enrolled · United States
- Apr 20, 2010BioTech Tools's first study: phase 1 study in Seasonal Allergic RhinoconjunctivitisNew to BioTech ToolsBioTech Tools · NCT01111279 · 27 enrolled · Belgium
- Dec 7, 2011Phase 2 study in Rhinitis, Allergic, SeasonalBioTech Tools · NCT01506375 · 24 enrolled · Belgium
- May 2, 2012Novavax's first studies: 2 phase 1 studies in Influenza, HumanNew to NovavaxNovavax · NCT01594320, NCT01596725
- Oct 3, 2012Immune Targeting Systems's first study: phase 1 study in Influenza ANew to Immune Targeting SystemsImmune Targeting Systems · NCT01701752 · 120 enrolled
- Nov 19, 2013Genocea Biosciences's first study: phase 1 study in Streptococcus PneumoniaeNew to Genocea BiosciencesGenocea Biosciences · NCT01995617 · 90 enrolled · United States
- Apr 11, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02114060 · 310 enrolled · United States
- Nov 20, 2014Phase 2 study in Herpes SimplexGenocea Biosciences · NCT02300142 · 37 enrolled · United States
- Apr 27, 2015Medigen Vaccine Biologics's first study: phase 2 study in H7N9 Influenza VaccineNew to Medigen Vaccine BiologicsMedigen Vaccine Biologics · NCT02436928 · 200 enrolled · Taiwan
- Jun 25, 2020Sanofi's first study: phase 1 study in Influenza, HumanNew to SanofiSanofi · NCT04451954 · 210 enrolled · United States
- Nov 16, 2022MAXVAX Biotechnology Limited Liability's first study: phase 1 study in Herpes ZosterNew to MAXVAX Biotechnology Limited LiabilityMAXVAX Biotechnology Limited Liability · NCT05636436 · 132 enrolled · China
- May 28, 2024Guangzhou Patronus Biotech's first study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to Guangzhou Patronus BiotechGuangzhou Patronus Biotech · NCT06442241 · 84 enrolled · Australia
- Aug 12, 2025Serum Institute of India Pvt.'s first study: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaNew to Serum Institute of India Pvt.Serum Institute of India Pvt. · NCT07147400 · 1,200 enrolled · Mali
- Sep 1, 2026Yikang Biotech (Suzhou)'s first study: phase 1 study in Respiratory Syncytial Virus (RSV)New to Yikang Biotech (Suzhou)Yikang Biotech (Suzhou) · NCT07807449 · 128 planned · China
Ahead
- Jan 22, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus (RSV)Yikang Biotech (Suzhou) · NCT07807449
- Nov 2027Primary completion: phase 2 study in Prevention of Malaria Transmission and Clinical MalariaSerum Institute of India Pvt. · NCT07147400
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07807449Respiratory Syncytial Virus (RSV) · China | 1 | Not yet recruiting | Yikang Biotech (Suzhou) | Jan 22, 2027 | 128 |
| NCT07147400Prevention of Malaria Transmission and Clinical Malaria · Mali | 2 | Active, not recruiting | Serum Institute of India Pvt. | Nov 2027 | 1,200 |
| NCT06442241Respiratory Syncytial Virus Infections · Australia | 1 | Active, not recruiting | Guangzhou Patronus Biotech | Dec 30, 2025 | 84 |
| NCT05636436Herpes Zoster · China | 1 | Completed | MAXVAX Biotechnology Limited Liability | May 23, 2025 | 132 |
| NCT04451954Influenza, Human · United States | 1 | Completed | Sanofi | Sep 20, 2021 | 210 |
| NCT02436928H7N9 Influenza Vaccine · Taiwan | 2 | Completed | Medigen Vaccine Biologics | Feb 2016 | 200 |
| NCT02300142Herpes Simplex · United States | 2 | Completed | Genocea Biosciences | Jun 2016 | 37 |
| NCT02114060Herpes Simplex · United States | 2 | Completed | Genocea Biosciences | Feb 2016 | 310 |
| NCT01995617Streptococcus Pneumoniae · United States | 1 | Completed | Genocea Biosciences | Feb 2015 | 90 |
| NCT01701752Influenza A | 1 | Completed | Immune Targeting Systems | Apr 2013 | 120 |
| NCT01596725Influenza, Human · United States | 1 | Completed | Novavax | Aug 2012 | 333 |
| NCT01594320Influenza, Human · United States | 1 | Completed | Novavax | Jul 2012 | 333 |
| NCT01506375Rhinitis, Allergic, Seasonal · Belgium | 2 | Completed | BioTech Tools | Jan 2013 | 24 |
| NCT01111279Seasonal Allergic Rhinoconjunctivitis · Belgium | 1 | Completed | BioTech Tools | Sep 2010 | 27 |
| NCT00662272Influenza, Human · United States | 1 | Completed | colby-pharmaceutical-company | Oct 2008 | 128 |
How it is read
Names in the registry
- “Monovalent Avian Influenza VLP (H5N1); Adjuvant”, 6 entries
- “Matrix-M2 Adjuvant (25μg)”, 2 entries
- “Matrix-M2 Adjuvant (50μg)”, 2 entries
- “Matrix-M2 Adjuvant (75μg)”, 2 entries
- “Low dose adjuvant”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 6 studies
- Herpes Simplex, 2 studies
- Herpes Zoster, 1 study
- Malaria, 1 study
- Respiratory Syncytial Virus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.